All In Biotech

Drug Trial Radar · NCT07328581

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

A Phase IIa, Open-Label, Single-Arm Study With an Initial Safety Run-In and Dose Expansion of ICG318 (BCMA-CD19-IL-15/IL15sushi cCAR T) in Participants With Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
iCell Gene TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Lupus Nephritis (LN)

Interventions

  • ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionBiological

    Anti-BCMA, Anti-CD19 Compound CAR-T Cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events after ICG318 infusionTime frame: Starting day 0 and up to 1 year after ICG318 infusion.
  2. DORIS remission rateTime frame: Starting day 0 and assessed at 6 months, and 1 year after ICG318 infusion.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois · Not yet recruiting

  • New York Medical College

    Hawthorne, New York · Not yet recruiting

  • NorthWell

    New Hyde Park, New York · Recruiting

  • Fox Chase Cancer Center- Temple BMT

    Philadelphia, Pennsylvania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.